Combining TNF blockade with immune checkpoint inhibitors in patients with cancer
- PMID: 34226729
- DOI: 10.1038/s41584-021-00653-8
Combining TNF blockade with immune checkpoint inhibitors in patients with cancer
Comment in
-
Reply to: Combining TNF blockade with immune checkpoint inhibitors in patients with cancer.Nat Rev Rheumatol. 2021 Sep;17(9):577-578. doi: 10.1038/s41584-021-00654-7. Epub 2021 Jul 5. Nat Rev Rheumatol. 2021. PMID: 34226728 No abstract available.
Comment on
-
TNF in the era of immune checkpoint inhibitors: friend or foe?Nat Rev Rheumatol. 2021 Apr;17(4):213-223. doi: 10.1038/s41584-021-00584-4. Epub 2021 Mar 8. Nat Rev Rheumatol. 2021. PMID: 33686279 Free PMC article. Review.
References
-
- Montfort, A. et al. The TNF paradox in cancer progression and immunotherapy. Front. Immunol. 10, 1818 (2019). - DOI
-
- Balkwill, F. Tumour necrosis factor and cancer. Nat. Rev. Cancer 9, 361–371 (2009). - DOI
-
- Chen, A. Y., Wolchok, J. D. & Bass, A. R. TNF in the era of immune checkpoint inhibitors: friend or foe? Nat. Rev. Rheumatol. 17, 213–223 (2021). - DOI
-
- Bertrand, F. et al. TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma. Nat. Commun. 8, 2256 (2017). - DOI
-
- Perez-Ruiz, E. et al. Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. Nature 569, 428–432 (2019). - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
